Scienture Holdings, Inc.
Scienture Holdings, Inc. (NASDAQ Capital Market: The Stock Market LLC) operates as a specialty pharmaceutical company focused on the commercialization and development of products for cardiovascular and central nervous system diseases. The company's website is www.scientureholdings.com, with additional web properties… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Scienture Holdings, Inc. does
In the company’s own words
Scienture Holdings, Inc. (NASDAQ Capital Market: The Stock Market LLC) operates as a specialty pharmaceutical company focused on the commercialization and development of products for cardiovascular and central nervous system diseases. The company's website is www.scientureholdings.com, with additional web properties at www.scienture.com, www.trxadehealth.com, and www.rxintegra.com.
Scienture LLC, a wholly owned subsidiary acquired in July 2024, serves as the primary operating entity. The company has launched its first commercial product, ArbliTM (SCN-102), an oral liquid formulation of losartan potassium approved by the FDA in March 2025 for treating hypertension, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy. This represents the first and only FDA-approved liquid formulation of losartan available on the market. The company is also commercializing REZENOPYTM (SCN-110), a naloxone hydrochloride nasal spray at 10mg strength, representing the highest FDA-approved nasal spray dose for opioid overdose reversal.
The development pipeline includes several product candidates in various clinical stages. SCN-104 is a multi-dose dihydroergotamine mesylate injection pen for acute migraine and cluster headache treatment. SCN-106 represents a potential biosimilar based on Cathflo Activase for thrombotically occluded catheter management, developed in collaboration with Anthem Biosciences. SCN-107 is a long-acting bupivacaine injection suspension for postsurgical pain management, with intellectual property licensed from Innocore Technologies.
The company pursues a commercialization strategy leveraging dedicated U.S. sales and marketing resources through partnerships with contract sales organizations, combining field teams, virtual representatives, and omnichannel marketing. Scienture relies on third-party contract manufacturing organizations for all production operations across North America, Europe, and Asia. The intellectual property portfolio includes multiple issued and pending patents providing protection for formulation compositions and methods of use across its product candidates, with patent exclusivity extending through 2041 for key products.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- COMMACK, NY
- Fiscal year end
- December
- CIK
- 1382574
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Scienture Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Scienture Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Scienture Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Scienture Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Scienture Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”